SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN), a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, today sent a second letter to its stockholders outlining Illumina’s unrivaled track record of superior operational performance and financial success. The letter urges stockholders to reject Roche’s efforts to acquire Illumina at a grossly inadequate price, and reiterates the recommendation from Illumina’s Board that stockholders vote for the election of Illumina’s highly qualified director nominees at its 2012 Annual Meeting of Stockholders by completing the WHITE proxy card today.
